BridgeBio Pharma, Inc. / Fundamentals

    Income statement

    Net revenue
    €202.33M
    Cost of goods sold
    €6.48M
    Gross profit
    €195.84M
    SG&A expenses
    €341.92M
    R&D expenses
    €406.23M
    EBITDA
    -€552.20M
    D&A
    -€488.20K
    EBIT
    -€562.52M
    Interest expenses
    €113.82M
    EBT
    -€668.87M
    Tax expenses
    €4.67M
    Net income
    -€666.16M

    Cash flow statement

    Net deferred tax
    €0.00
    Non-cash items
    -€24.99M
    Changes in working capital
    €25.93M
    Operating cash flow
    -€562.68M
    Capex
    €8.63M
    Other investing cash flow
    -€9.37M
    Net investing cash flow
    €17.50M
    Total cash dividends paid
    €0.00
    Issuance of common stock
    -€15.44K
    Debt repayment
    €686.40M
    Other financing cash flow
    €35.92M
    Net financing cash flow
    €718.15M
    Foreign exchange effects
    €0.00
    Net change in cash
    €172.97M
    Cash at end of period
    €644.44M
    Free cash flow
    -€554.05M

    Balance sheet

    Cash and cash equivalents
    €642.99M
    Cash and short-term investments
    €649.80M
    Total receivables
    €65.95M
    Inventory
    €15.68M
    Other current assets
    €51.30M
    Total current assets
    €782.73M
    Property, plant & equipment
    €10.55M
    Goodwill
    €0.00
    Intangible assets
    €25.32M
    Long-term investments
    €94.12M
    Other non-current assets
    €14.08M
    Total non-current assets
    €144.07M
    Total assets
    €926.80M
    Accounts payable
    €22.42M
    Short-term debt
    €8.23M
    Other current liabilities
    €111.18M
    Total current liabilities
    €150.88M
    Long-term debt
    €2.29B
    Deferred tax liabilities
    €0.00
    Other non-current liabilities
    €467.61K
    Total non-current liabilities
    €2.30B
    Total liabilities
    €2.45B
    Common stock
    €169.88K
    Retained earnings
    -€2.96B
    Other equity
    €858.00
    Total equity
    -€1.53B
    Total liabilities and shareholders' equity
    €926.80M

    Company information

    Market capitalization
    €7.27B
    Employees
    725
    Enterprise Value
    €7.08B

    Company ratios

    Gross margin
    96.8% Much better than peer group: -20,080.7%
    EBITDA margin
    -272.9% Much better than peer group: -28,467.8%
    EBIT margin
    -278.0% Much better than peer group: -28,883.9%
    EBT margin
    -330.6% Much better than peer group: -29,683.4%
    Net margin
    -329.3% Much better than peer group: -29,253.4%
    ROE
    43.7% Much better than peer group: -116.3%
    ROA
    -71.9% Much worse than peer group: -50.3%
    Asset turnover
    21.8% Better than peer group: 16.7%
    FCF margin
    -282.4% Much better than peer group: -25,913.1%
    FCF yield
    -7.9%
    Efficiency ratio
    372.9%
    Net sales per employee
    €279.07K
    Net income per employee
    -€918.85K

    Notifications